#Canada #Toronto #AI Technology #Clinical Trials #NetraMark Holdings

NetraMark to Host Shareholder Conference Call

NetraMark Holdings Inc., a key player in artificial intelligence technology, is set to hold a significant conference call on April 15, 2025. The call aims to provide shareholders with crucial updates on the company's strategic developments, commercial progress, and regulatory initiatives. CEO George Achilleos will lead the discussion, highlighting how NetraMark is transforming clinical trials through AI-powered precision analytics.

Key Highlights to be Discussed

The upcoming conference call is not only an opportunity for shareholders to gain insights into NetraMark's current operations but also to understand the future direction of the company. Here are the main topics that will be covered during the session:

Strategic Partnerships

One of the key developments is NetraMark's recent partnership with a global contract research organization (CRO), Worldwide Clinical Trials. This collaboration aims to integrate NetraAI technology into a wider array of clinical trials, particularly focusing on vital fields such as neuroscience and oncology. This partnership is expected to increase the exposure and adoption of NetraMark's groundbreaking technology.

Regulatory Strategies

The call will also delve into NetraMark's approach to regulatory alignment. The company plans to share details about its innovative use of explainable AI capabilities that enhance the quality of submissions to regulatory bodies such as the FDA. This strategy is critical for ensuring compliance and fostering trust with regulatory authorities, which is essential for the success of clinical trials.

Technology Differentiation

Attendees can expect to hear about what sets NetraAI apart from traditional AI methodologies. The company emphasizes actionable insights and the ability to identify subpopulations in small datasets, addressing common issues like overfitting. This unique capability will be showcased alongside future enhancements and practical applications of its technology, underscoring NetraMark's commitment to advancing the industry's standards.

Call Logistics

• - Date: Tuesday, April 15, 2025
• - Time: 4:00 PM to 4:30 PM EST
• - Dial-in Number: (CA) 1-605-313-5544 (Access Code 8003978#)
• - Video Call Link: Join Here

A recorded version of the call will be available on NetraMark's website, allowing those who cannot attend to catch up on all critical details.

Marketing and Investor Relations Update

In addition to the call, NetraMark has extended its agreement with 1502656 B.C. LTD., enhancing its public relations efforts. The term of this agreement has been extended by six months to increase awareness and engagement with potential investors. This strategic move will allow the company to refine its communication strategy while providing additional compensation to support its marketing efforts.

About NetraAI

NetraAI's framework is not just another AI solution; it's engineered to delineate small datasets into explainable and unexplainable subsets, which help to tailor insights better for medical research applications. The explainable AI aspect allows for deeper insights into treatment effects, which could lead to significantly improved clinical trial outcomes. Unlike conventional AI methods, NetraAI actively avoids the pitfalls of overfitting, positioning itself as a revolutionary tool in clinical research.

About NetraMark

In summary, NetraMark is dedicated to pioneering advancements in Generative Artificial Intelligence and machine learning tailored specifically for the pharmaceutical sector. Its unique algorithmic approach allows for deep dives into patient datasets, achieving accuracy even with smaller pools of data. This capability ensures that drugs can be accurately evaluated with regards to their effectiveness and patient sensitivity.

For more information, interested parties can refer to NetraMark's official documents available on SEDAR+.

As the company embarks on this exciting phase of growth and transformation, make sure to tune into the conference call for first-hand insights and strategic vision, directly from the leadership team.